Australia - inglés - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - amoxycillin as amoxycillin trihydrate; clavulanic acid as potassium clavulanate - oral tablet - amoxycillin as amoxycillin trihydrate antibiotic active 40.0 mg/tb; clavulanic acid as potassium clavulanate antibiotic active 10.0 mg/tb - antibiotic & related - cat | dog | bitch | castrate | cat - queen | cat - tom | kitten | puppy - bordetella bronchiseptica | corynebacterium spp. | escherichia coli (e. coli) | klebsiella spp. | pasteurella spp. | proteus mirabilis | salmonella | staphylococcus spp. | streptococcus spp. | bacterial canker | canine cough syndrome | including b-lactamase producin | infectious tracheobronchitis | pasterellosis | pasteurellosis | salmonellosis | staphylococcosis

Australia - inglés - APVMA (Australian Pesticides and Veterinary Medicines Authority)

dechra veterinary products (australia) pty. ltd. - amoxycillin as amoxycillin trihydrate; clavulanic acid (as potassium salt) - oral tablet - amoxycillin as amoxycillin trihydrate antibiotic active 160.0 mg/tb; clavulanic acid (as potassium salt) antibiotic active 40.0 mg/tb - antibiotic & related - cat | dog | bitch | castrate | cat - queen | cat - tom | kitten | puppy - bacterial infection | amoxycillin sensitive bacteria | associated with viral disease | gram negative organisms | gram positive organisms | post parturient bacterial infe | primary bacterial infection | sulfadiazine sensitive bacteri | trimethoprim sensitive bacteri | tylosin sensitive bacteria

Australia - inglés - Department of Health (Therapeutic Goods Administration)

medreich australia pty ltd - potassium clavulanate, quantity: 148.875 mg; amoxicillin trihydrate, quantity: 1006.25 mg - tablet, film coated - excipient ingredients: ethylcellulose; isopropyl alcohol; microcrystalline cellulose; purified talc; dichloromethane; magnesium stearate; propylene glycol; croscarmellose sodium; hypromellose; titanium dioxide; hyprolose; industrial methylated spirit - medreich co-amoxiclav 500/125 and medreich co-amoxiclav 875/125 tablets are indicated for short term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology):,urinary tract infections (uncomplicated and complicated),lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis,upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis.,skin and skin structure infection,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to amoxicillin and clavulanic acid tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate.,the treatment of mixed infections caused by amoxicillin susceptible organisms and beta-lactamase producing organisms susceptible to amoxicillin and clavulanic acid tablets should not require the addition of another antibiotic due to the amoxicillin content of these products.

Australia - inglés - Department of Health (Therapeutic Goods Administration)

medreich australia pty ltd - potassium clavulanate, quantity: 148.875 mg; amoxicillin trihydrate, quantity: 575 mg - tablet, film coated - excipient ingredients: propylene glycol; dichloromethane; hypromellose; magnesium stearate; croscarmellose sodium; ethylcellulose; purified talc; isopropyl alcohol; microcrystalline cellulose; titanium dioxide; hyprolose; industrial methylated spirit - medreich co-amoxiclav 500/125 and medreich co-amoxiclav 875/125 tablets are indicated for short term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology):,urinary tract infections (uncomplicated and complicated),lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis,upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis.,skin and skin structure infection,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to amoxicillin and clavulanic acid tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate.,the treatment of mixed infections caused by amoxicillin susceptible organisms and beta-lactamase producing organisms susceptible to amoxicillin and clavulanic acid tablets should not require the addition of another antibiotic due to the amoxicillin content of these products.

Australia - inglés - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - potassium clavulanate, quantity: 13.58 mg/ml (equivalent: clavulanic acid, qty 11.4 mg/ml); amoxicillin trihydrate, quantity: 91.84 mg/ml (equivalent: amoxicillin, qty 80 mg/ml) - suspension, powder for - excipient ingredients: citric acid; guar gum; sodium citrate; purified talc; aspartame; silicon dioxide; flavour - short-term treatment of the following bacterial infections when caused by sensitive organisms: skin and skin structure infections; urinary tract infections (complicated and uncomplicated); upper respiratory tract infections including sinusitis and otitis media; lower respiratory tract infections including acute exacerbations of chronic bronchitis and community acquired pneumonia. appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to curam duo 400/57. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed in microbiology, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to curam duo 400/57 should not require the addition of another antibiotic due to the amoxycillin content of curam duo 400/57.

Australia - inglés - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - amoxicillin, quantity: 500 mg; clavulanic acid, quantity: 125 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; sodium starch glycollate; microcrystalline cellulose; magnesium stearate; titanium dioxide; hypromellose; propylene glycol; purified talc; ethylcellulose - augmentin tablets are indicated for short term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology): urinary tract infections (uncomplicated and complicated); lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis; upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis; skin and skin structure infections. appropriate culture and susceptibility studies should be performed to identify the causative organisms(s) and its (their) susceptibility to augmentin tablets. however, when there is reason to believe an infection may involve any of the b-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxycillin susceptible organisms and b-lactamase producing organisms susceptible to augmentin tablets should not require the addition of another antibiotic due to the amoxycillin content of these products.

Sudáfrica - inglés - South African Health Products Regulatory Authority (SAHPRA)

sandoz south africa (pty) ltd - tablet - see ingredients - each tablet contains amoxycillin trihydrate equivalent to amoxycillin 875,0 mg potassium clavulanate equivalent to clavulanic acid 125,0 mg

Sudáfrica - inglés - South African Health Products Regulatory Authority (SAHPRA)

adcock ingram limited - tablet - each tablet contains amoxycillin trihydrate equivalent to amoxycillin 875,0 mg potassium clavulanate equivalent to clavulanic acid 125,0 mg

Sudáfrica - inglés - South African Health Products Regulatory Authority (SAHPRA)

sandoz south africa (pty) ltd - tablet - see ingredients - each tablet contains amoxycillin trihydrate equivalent to amoxycillin 875,0 mg potassium clavulanate equivalent to clavulanic acid 125,0 mg

Sudáfrica - inglés - South African Health Products Regulatory Authority (SAHPRA)

merck generics rsa (pty) ltd - tablet - see ingredients - each tablet contains amoxycillin trihydrate equivalent to amoxycillin 875,0 mg potassium clavulanate equivalent to clavulanic acid 125,0 mg